Matthieu Mahévas

Matthieu Mahévas

Auto-generated profile, based on publicly available information

Matthieu Mahévas

Service de Médecine Interne, Centre National de Référence des Cytopénies Auto‐Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP‐HP) Université Paris Est Créteil Créteil France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Cell
Verified
Journal Article
Closed access
ASAurélien Sokal
Aurélien Sokal
PCPascal Chappert
Pascal Chappert
GBGiovanna Barba-Spaeth
Giovanna Barba-Spaeth
ARAnais Roeser
Anais Roeser
SFSlim Fourati
Slim Fourati
MMMatthieu Mahévas
Matthieu Mahévas

14 May 2020 in BMJ
Verified
Journal Article
Open access
PDF file
MMMatthieu Mahévas
Matthieu Mahévas
VTViet-Thi Tran
Viet-Thi Tran
MRMathilde Roumier
Mathilde Roumier
ACAmélie Chabrol
Amélie Chabrol
RPRomain Paule
Romain Paule
NCNathalie Costedoat-Chalumeau
Nathalie Costedoat-Chalumeau
Objective: To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design: Comparative observational study using data collected from routine care. Setting: Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020. Participants: 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care. Interventions: Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group). Main outcome measures: The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress syndrome, weaning from oxygen, and discharge from hospital to home or rehabilitation (all at day 21). Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results: In the main analysis, 84 patients who received hydroxychloroquine within 48 hours of admission to hospital (treatment group) were compared with 89 patients who did not receive hydroxychloroquine (control group). Eight additional patients received hydroxychloroquine more than 48 hours after admission. In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment. Conclusions: Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen.

1 November 2020 in Journal of Infection
Verified
Journal Article
Open access
MGMarie Gousseff
Marie Gousseff
PPPauline Penot
Pauline Penot
LGLaure Gallay
Laure Gallay
DBDominique Batisse
Dominique Batisse
NBNicolas Benech
Nicolas Benech
EBElisabeth Botelho-Nevers
Elisabeth Botelho-Nevers
For the first 3 months of COVID-19 pandemic, COVID-19 was expected to be an immunizing non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID-19 patients having experienced a second clinically- and virologically-confirmed acute COVID-19 episode. According to the clinical history, we discuss either re-infection or reactivation hypothesis. Larger studies including further virological, immunological and epidemiologic data are needed to understand the mechanisms of these recurrences.

21 September 2021 in Immunity
Verified
Journal Article
Closed access
ASAurélien Sokal
Aurélien Sokal
GBGiovanna Barba-Spaeth
Giovanna Barba-Spaeth
IFIgnacio Fernández
Ignacio Fernández
MBMatteo Broketa
Matteo Broketa
IAImane Azzaoui
Imane Azzaoui
MMMatthieu Mahévas
Matthieu Mahévas

1 May 2020 in Kidney International
Verified
Journal Article
Closed access
ECEtienne Crickx
Etienne Crickx
JWJean-Claude Weill
Jean-Claude Weill
CRClaude-Agnès Reynaud
Claude-Agnès Reynaud
MMMatthieu Mahévas
Matthieu Mahévas

14 April 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ECEtienne Crickx
Etienne Crickx
PCPascal Chappert
Pascal Chappert
ASAurélien Sokal
Aurélien Sokal
SWSandra Weller
Sandra Weller
IAImane Azzaoui
Imane Azzaoui
MMMatthieu Mahévas
Matthieu Mahévas
Rituximab-resistant memory B cells and newly engaged naive B cells join to fuel subsequent autoimmune responses in patients with relapsing ITP.